Code intelligence

FDA-NDA215383 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA215383.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: WELIREG (BELZUTIFAN) — Type 1 - New Molecular Entity

Policy FDA-NDA215383 · Oncology

High

WELIREG (Belzutifan) is an oral medication and will fall under Medicare Part D for coverage. There are no applicable J-codes as it is not an injectable drug, and existing alternatives may affect adopt

View alert